$SGHT

Sight Sciences (SGHT) announced FDA expanded the TearCare System's use to improve meibomian gland function in adults with evaporative dry eye disease due to MGD. This makes TearCare the first treatment indicated for this purpose, according to the company. The update also includes optional debridement, enhancing its approach to treating the condition. SGHT reported Q2 2026 revenue growth and updated its full-year guidance earlier this month.

Sight Sciences (SGHT) announced FDA approval for its TearCare System to improve meibomian gland function in patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD). This makes TearCare the first and only treatment indicated for this purpose, expanding its market potential. The company's CEO and a medical expert highlighted the significance of this milestone in dry eye disease treatment.

Sight Sciences (SGHT) reported Q2 2026 revenue of $23.4M, up 20% y/y, driven by Interventional Glaucoma ($20.7M) and Interventional Dry Eye ($2.7M). Gross margin rose to 91% from 85%. Net loss was $4.4M. FY2026 revenue guidance raised to $88M-$92M; adjusted opex guidance lowered to $92M-$94M. Alcon patent appeal remains pending.

Sight Sciences, Inc. (SGHT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Appointment of Chief Legal Officer On August 6, 2026, the Board of Directors (the “Board”) of Sight Sciences, Inc. (the “Com

Biotech gainers included Creative Medical (CELZ), up 71.95% after a new U.S. patent for exosome-based immunotherapy for Type 1 diabetes. Braveheart Bio (BRVE) jumped 65.56% on its Nasdaq debut. Iovance (IOVA) rose 43.09% after Q2 product revenue rose 66% to about $99M. Sight Sciences (SGHT) gained 27.75% after raising 2026 revenue guidance to $88M-$92M.

Sight Sciences, Inc. (SGHT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sight Sciences Reports Second Quarter 2026 Financial Results Raises Full-Year 2026 Revenue Guidance and Reduces Adjusted Operating Expense Guidance MENLO PARK, Calif., August 5, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Compa

Sight Sciences (SGHT) said the FDA granted 510(k) clearance for its OMNI Ultra Surgical System, a handheld single-use device for minimally invasive glaucoma surgery. The system is indicated for canaloplasty followed by trabeculotomy to lower intraocular pressure in adults with primary open-angle glaucoma. The company plans a U.S. commercial launch in Q4 2026.

Encrantz Staffan purchased 14,100 shares of Sight Sciences, Inc. (SGHT) at $4.88 on 2026-06-10.

Sight Sciences, a medical technology company specializing in eye diseases, particularly glaucoma, is under investor focus following its recent earnings report and FDA updates. The company's revenue is driven by its glaucoma surgery platform, with growth influenced by procedure volumes, reimbursement trends, and surgeon adoption, while also investing in commercialization and R&D. While competition is intense, Sight Sciences positions itself through focused innovation and engagement with ophthalmic surgeons, making clinical data, competition, and healthcare policy key factors for investors to monitor.

Sight Sciences (NASDAQ: SGHT) CTO David Badawi sold 8,168 shares of the company's stock on April 2nd at an average price of $3.48, totaling approximately $28,424. This sale reduced his position by 0.41% to 1,990,290 shares. The company's stock has a 12-month range of $2.03-$9.24 and a "Hold" consensus rating from analysts with an $8.31 average target price.